The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

nextgenjane.com

Founded Year

2014

Stage

Debt | Alive

Total Raised

$14.34M

Last Raised

$1.5M | 2 mos ago

About NextGen Jane

NextGen Jane offers women insights into their reproductive health through a genomics-driven approach to tracking biological changes predictive of disease. Its smart tampon allows women to proactively keep track of their health by studying blood samples in the privacy of their homes. The company was founded in 2014 and is based in Oakland, California.

NextGen Jane Headquarter Location

400 29th Street Suite 105

Oakland, California, 94609,

United States

925-526-5263

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing NextGen Jane

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned NextGen Jane in 2 CB Insights research briefs, most recently on May 12, 2021.

Expert Collections containing NextGen Jane

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NextGen Jane is included in 5 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,471 items

Startups focused on providing products and services catering to women's health and wellbeing.

B

Beauty & Personal Care

858 items

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

M

Medical Devices

8,454 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

NextGen Jane Patents

NextGen Jane has filed 3 patents.

The 3 most popular patent topics include:

  • DNA
  • Molecular biology
  • Chemical tests
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/6/2016

3/20/2018

Molecular biology, DNA, Manned spacecraft, Vagina, Fluid dynamics

Grant

Application Date

7/6/2016

Grant Date

3/20/2018

Title

Related Topics

Molecular biology, DNA, Manned spacecraft, Vagina, Fluid dynamics

Status

Grant

Latest NextGen Jane News

NextGen Jane Awarded NIH Grants

Feb 22, 2022

February 22, 2022 10:00 AM Eastern Standard Time OAKLAND, Calif.--( BUSINESS WIRE )-- NextGen Jane , a genomics startup generating big data for novel applications in molecular diagnostics and drug development for female reproductive disorders, announced that it has received the green light for the second phase of a Small Business Innovation Research (SBIR) Fast Track grant by the Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD), part of National Institutes of Health (NIH). The two phase, multi-year grant will provide continued funding for the development and advancement of a non-invasive tampon-based test for endometriosis, a common and debilitating condition which affects 10 to 15% of females, gives rise to pain, and is a frequent cause of infertility. “We are excited to receive this financial support from NICHD and be a part of their concerted effort to address gynecologic conditions which are debilitating for half the population,” said Ridhi Tariyal, co-founder and Chief Executive Officer of NextGen Jane. “To overcome a significant barrier in helping women with endometriosis, it is critical to increase disease awareness through convenient at-home testing. The path paved over the past two years for at-home diagnostic tests highlights the receptiveness of people across the globe to early diagnosis through ‘at home’ testing. This competitive NIH grant helps NextGen Jane take the next steps in developing the big data analytic tools needed to establish the molecular signature of this novel non-invasive diagnostic for patients in obstetrics and gynecological care and for women who want greater control of their own health.” In Phase 1, NextGen Jane was awarded $267,669 to further explore biomarkers of endometriosis in menstrual effluence. For Phase 2, NextGen Jane has been awarded $1,518,169 for the next 2 years to test the performance of menstrual-based classifiers of endometriosis. Separately, NextGen Jane is also a sub-awardee on an NIH NICHD R01 (Research Project Grant) based in Baylor College of Medicine’s Center for Drug Discovery. As a sub-awardee, NextGen Jane will apply their data tools toward the development of companion diagnostics to help stratify patient populations who are high probability responders to specific drug profiles. The collaborative effort with Baylor, located in the world’s largest medical center, the Texas Medical Center in Houston, will help build and validate NextGen Jane’s platform precision medicine objectives. Principal Investigator and Associate Professor at Baylor, Dr. Stephen Palmer, added, “For more than 40 years, women have been treated with a ‘one-size-fits-all’ approach to diagnosis and medical treatment through laparoscopy and suppressing the action of estrogen on endometriosis. Over time, endometriosis lesions escape detection and establish their own ability to make estrogen. The Baylor Department of Pathology & Immunology and Center for Drug Discovery is working with NextGen Jane to identify novel molecular signatures of this escape. The signatures that are emerging from hormone-resistant endometriosis are dominated by inflammatory pathways. Our therapeutic strategy is to help the body channel its own inflammatory response towards suppression of disease, and to demonstrate disease minimization with the NextGen Jane platform through a second molecular signature of disease remission.” About NextGen Jane NextGen Jane is a genomic startup pairing next generation sequencing with cells shed naturally from the female reproductive tract to reformat diagnostics and therapeutics. By developing analytics based on molecular signals found in menstrual effluence, NextGen Jane is reframing how women engage with their health. A simple and elegant tampon collection kit enables serial sample collection, longitudinal data generation and efficient scaling across disease areas. In the near term, the company is developing ways to provide diagnostic insight into uterine pathologies such as endometriosis or heavy menstrual bleeding. Contacts

NextGen Jane Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NextGen Jane Rank

  • When was NextGen Jane founded?

    NextGen Jane was founded in 2014.

  • Where is NextGen Jane's headquarters?

    NextGen Jane's headquarters is located at 400 29th Street, Oakland.

  • What is NextGen Jane's latest funding round?

    NextGen Jane's latest funding round is Debt.

  • How much did NextGen Jane raise?

    NextGen Jane raised a total of $14.34M.

  • Who are the investors of NextGen Jane?

    Investors of NextGen Jane include National Institutes of Health, David Walt, Rox Anderson, Kacey Fitzpatrick, Steve Quake and 13 more.

  • Who are NextGen Jane's competitors?

    Competitors of NextGen Jane include DotLab.

You May Also Like

T
Temple Therapeutics

Temple Therapeutics is a pharmaceutical clinical development company with a global footprint, focused on diseases where abnormal tissue growth and dysfunction are common hallmarks and lead to fibrosis, pain, infertility, and cancers. The company was founded in 2020 and is based in Geleen, Netherlands.

DotLab Logo
DotLab

DotLab is developing a non-invasive test for endometriosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.